Cybin Inc
Research Cybin Inc (HELP) on Bullrun: market cap USD 866.85M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHELP
- ExchangeNYSE MKT
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 866.85M
- Financial periodQ1 2026
- RevenueCAD 0
- Net income-CAD 47.00M
- Free cash flow-CAD 37.61M
Valuation Snapshot
latest market cap is USD 866.85M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | -CAD 131.58M | -CAD 119.23M | n/a | -9.08 | CAD 195.13M | CAD 28.89M | CAD 273.93M |
| FY2024 | n/a | n/a | n/a | n/a | -2.93 | CAD 136.29M | CAD 0 | CAD 240.24M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 866.85M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 408.13M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 176.41M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 166.64M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 52.46M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 651.26M | n/a | n/a | n/a |
About Cybin Inc
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cybin Inc's market cap?
Cybin Inc's market capitalization is USD 866.85M.
What does Cybin Inc do?
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system.